Moreover, the macrophage-related gene signature was found to be predictive of the targeted therapy outcome in glioma patients and outperformed existing gene signatures including conventional EGFR signature [15, 16] and an immune-related gene signature [17], which were verified using the validation dataset. Here, EGFR is linked to glioma.